Abstract | BACKGROUND: METHODS: In this prospective, single-center open-label research study, safety and efficacy outcomes were evaluated in patients on HPN younger than 18 years treated with CLE at 1 to 3 g · kg-1 · day-1 over 12 months. The primary outcome was change in anthropometrics and GIRs compared with baseline. Secondary outcomes were changes in fatty acid profiles and liver function and enzyme tests compared with baseline. RESULTS: Fifty-seven subjects were treated with a median age of 7 years. The diagnosis was short bowel syndrome in 72%. Change in practice was associated with a decrease in mean GIRs from 17 to 14 mg · kg-1 · h-1 at 4 to 6 months postbaseline and beyond with a coincidental decline in mean arachidonic acid and stable growth parameters. No significant adverse events were noted. CONCLUSIONS: CLE was safe and well-tolerated in stable children on HPN at 1 year, but further studies are needed in this population to appreciate long-term outcomes.
|
Authors | Bram P Raphael, Paul D Mitchell, Alexandra Carey, Kathleen M Gura, Mark Puder |
Journal | Journal of pediatric gastroenterology and nutrition
(J Pediatr Gastroenterol Nutr)
Vol. 72
Issue 3
Pg. 451-455
(03 01 2021)
ISSN: 1536-4801 [Electronic] United States |
PMID | 33264184
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright © 2020 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. |
Chemical References |
- Fat Emulsions, Intravenous
- Fish Oils
- Olive Oil
- Triglycerides
- Soybean Oil
|
Topics |
- Adult
- Child
- Fat Emulsions, Intravenous
- Fish Oils
- Humans
- Olive Oil
- Parenteral Nutrition, Home
(adverse effects)
- Prospective Studies
- Soybean Oil
- Triglycerides
|